Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in natural infection and elicitation of HIV-1 bnAbs has not been achieved by any vaccine candidates. We and others have reported that HIV-1 bnAbs are highly diversified from their germline-like predecessors and the germline-like predecessors of bnAbs lack measurable binding to HIV-1 envelope (Env) glycoproteins, suggesting that Env structures containing the epitopes of bnAbs may not initiate somatic maturation pathway, which may partially explain the rarity of HIV-1 bnAbs. To determine the minimum mutations required for converting non-binding germline-like predecessors to Env-binding antibodies, we started with the bnAb b12 as a prototype and gener...
Elicitation of VRC01-class broadly neutralizing antibodies (bnAbs) is an appealing approach for a pr...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
An effective HIV-1 vaccine will likely elicit broadly neutralizing antibodies (bnAbs). However, deve...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
HIV-1 broadly neutralizing antibodies (bnAbs) with great potency and breadth have been identified fr...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Broadly neutralizing antibodies (bNAbs) against HIV-1 have been increasingly isolated since 2009. Th...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Summary Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)...
Elicitation of VRC01-class broadly neutralizing antibodies (bnAbs) is an appealing approach for a pr...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
An effective HIV-1 vaccine will likely elicit broadly neutralizing antibodies (bnAbs). However, deve...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
HIV-1 broadly neutralizing antibodies (bnAbs) with great potency and breadth have been identified fr...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Broadly neutralizing antibodies (bNAbs) against HIV-1 have been increasingly isolated since 2009. Th...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Summary Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)...
Elicitation of VRC01-class broadly neutralizing antibodies (bnAbs) is an appealing approach for a pr...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...